Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy

NCT02104830 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT02104830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02104830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2013
Completion date
October 31, 2014
Enrollment
135 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia